112663-43-1

Basic information

• Product Name: Methanesulfonic acid 3-tert-butoxycarbonylaMino-propyl ester
• Synonyms: Methanesulfonic acid 3-tert-butoxycarbonylaMino-propyl ester;3-(tert-butoxycarbonyl)propyl methanesulfonate;3-(tert-butoxycarbonylamino)propyl methanesulfonate;methanesulfonic acid 3-tert-butoxycarbonylaminopropyl
• CAS NO: 112663-43-1
• Molecular Formula: C₉H₁₉NO₅S
• Molecular Weight: 253.31586
• Mol File: 112663-43-1.mol
• Article Data: 47

Chemical Properties

• Boiling Point: 413.6±28.0 °C(Predicted)
• Appearance: /
• Density: 1.168±0.06 g/cm3(Predicted)
• PKA: 12.44±0.46(Predicted)
• CAS DataBase Reference: Methanesulfonic acid 3-tert-butoxycarbonylaMino-propyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Methanesulfonic acid 3-tert-butoxycarbonylaMino-propyl ester(112663-43-1)
• EPA Substance Registry System: Methanesulfonic acid 3-tert-butoxycarbonylaMino-propyl ester(112663-43-1)

Safety Data

• Hazardous Substances Data: 112663-43-1(Hazardous Substances Data)

Usage

General Description

Methanesulfonic acid 3-tert-butoxycarbonylaMino-propyl ester is a chemical compound with the molecular formula C10H21NO4S. It is commonly used in organic synthesis as a protecting group for amino groups, particularly in peptide synthesis. Methanesulfonic acid 3-tert-butoxycarbonylaMino-propyl ester is a derivative of methanesulfonic acid, which is a strong acid commonly used as a catalyst in various chemical reactions. The 3-tert-butoxycarbonylaMino-propyl ester group serves as a protective group for the amino group, allowing for selective reactions to occur at other functional groups without affecting the amino group. Additionally, this compound is often used in pharmaceutical research and development for the synthesis of new drugs and pharmaceutical intermediates.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 58885-58-8 N-tert-butoxycarbonyl-3-aminopropanol 
• 7143-01-3 Methanesulfonic anhydride 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 753483-45-3 (3-pyrazolo[4,5-b]pyridin-1-ylpropyl)carbamic acid tert-butyl ester 
• 753483-44-2 (3-pyrazolo[4,5-b]pyridin-2-ylpropyl)carbamic acid tert-butyl ester 
• 1415658-00-2 tert-butyl (S)-(3-(3-(((3-iodobenzyl)oxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)propyl)carbamate 
• 425644-03-7 N⁸-benzyloxycarbonyl-N¹-tert-butyloxycarbonyl-N⁴-(2-nitrobenzenesulfonyl)-spermidine 
• 1202757-90-1 tert-butyl 3-(3-(4-(3-acrylamidophenylamino)-5-fluoropyrimidin-2-ylamino)phenoxy)propylcarbamate 
• 1202760-20-0 C₂₄H₂₇FN₆O₅ 
• 1202760-21-1 C₂₄H₂₉FN₆O₃ 
• 1426687-03-7 tert-butyl (3-(((4S)-6-(4-chlorophenyl)-4-(2-(ethylamino)-2-oxoethyl)-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-8-yl)oxy)propyl)carbamate 

Relevant articles and documents

Synthesis and biological evaluation of dihydromotuporamine derivatives in cells containing active polyamine transporters

Dihydromotuporamine C (4) and its 4,4-triamine analogue (5) were synthesized in good yield using ring-closing metathesis (RCM) methods. Comparison of their biological activities (Ki determinations in L1210 cells and IC50 determinations in L1210, CHO, and CHO-MG cells) revealed that the motuporamine derivatives do not use the polyamine transporter (PAT) for cellular entry. Bioevaluation of a N1-(anthracen-9- ylmethyl)-n1-(ethyl)homospermidine control (7) revealed that the presence of a N1 tertiary amine center imparted a significant reduction in the PAT affinity of the polyamine conjugate and abolished its PAT-targeting selectivity.

Mono-Protected Diamines. Nα-tert-Butoxycarbonyl α,ω-Alkanediamine Hydrochlorides from Amino alcohols.

Nα-tert-Butoxycarbonyl α,ω-alkanediamine hydrochlorides 3a-e are prepared from the amino alcohols in yields of 66-87percent.Reaction of the free amine with di-tert-butyl dicarbonate gives the N-tert-Butoxycarbonylamino alcohol 1a-e.One-pot conversion to the azide 2a-e via the mesylate under phase-transfer conditions followed by hydrogenolysis in the presence of chloroform yields the title compounds.

Discovery of Potential Neuroprotective Agents against Paclitaxel-Induced Peripheral Neuropathy

Chemotherapy-induced neurotoxicity is a common adverse effect of cancer treatment. No medication has been shown to be effective in the prevention or treatment of chemotherapy-induced neurotoxicity. Using minoxidil as an initial template for structural modifications in conjunction with an in vitro neurite outgrowth assay, an image-based high-content screening platform, and mouse behavior models, an effective neuroprotective agent CN016 was discovered. Our results showed that CN016 could inhibit paclitaxel-induced inflammatory responses and infiltration of immune cells into sensory neurons significantly. Thus, the suppression of proinflammatory factors elucidates, in part, the mechanism of action of CN016 on alleviating paclitaxel-induced peripheral neuropathy. Based on excellent efficacy in improving behavioral functions, high safety profiles (MTD > 500 mg/kg), and a large therapeutic window (MTD/MED > 50) in mice, CN016 might have great potential to become a peripherally neuroprotective agent to prevent neurotoxicity caused by chemotherapeutics as typified by paclitaxel.

MACROCYCLIC KINASE INHIBITOR

Disclosed is a macrocyclic kinase inhibitor, wherein the compound, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof is as shown in formula I. Experiments show that the new compound as shown in formula I disclosed in the present invention exhibits an excellent TRK inhibitory activity, has a significant inhibitory effect on TRKA-mutant cell growth, and exhibits an excellent inhibitory effect on in vivo tumor growth, thus providing a new choice for the clinical treatment of diseases associated with abnormal TRK activity.